bluuebunny/crossref_metadata_2025_split huggingface dataset:
STUDI ANALISIS DAYA DUKUNG PONDASI ABUTMENT JEMBATAN KALIGAWE KOTA SEMARANG
Authors: Nurinayah Titin , Yuwana Dwi Sat Agus , . Yusfita 
Published: August 2021

Pemilihan jenis pondasi serta analisis daya dukungnya harus cermat, hal ini dikarenakan kekuatan pondasi sebagai pendukung struktur atas akan sangat mempengaruhi kekuatan berdirinya suatu bangunan. Sehingga diperlukan analisis mengenai kekuatan atau daya dukung pondasi dengan perhitungan manual dan pemodelan. Objek penelitian ini adalah Jembatan Kaligawe dengan pondasi tiang pancang sebagai struktur bawahnya yang terletak di Kota Semarang, Provinsi Jawa Tengah. Metode yang digunakan adalah Mayerhof serta software Plaxis 2D V.8.6 sebagai alat bantu hitung dan pemodelan. Dari metode Mayerhof didapatkan nilai daya dukung ultimit dan stabilitas geser serta guling arah x dan y. Sedangkan untuk <em>software</em> Plaxis 2D V.8.6 menghasilkan nilai keamanan pondasi secara keseluruhan.Hasil penelitian menunjukkan bahwa daya dukung pondasi tiang pancang (Qu) yang dianalisis dengan metode Mayerhof sebesar 1348 kN, dan angka keamanan terendah terdapat pada stabilitas geser abutmen arah x sebesar 3.1 pada kombinasi-3 dan kombinasi-4, sedangkan angka keamanan pondasi secara keseluruhan dari perhitungan Plaxis 2D V.8.6 sebesar 39.9.
ILT20 – an Upgraded Computer Program for Evaluation of Accelerated Leach Test Data of LLW in the Hungarian NPP Paks
Authors: Pátzay György , Nyőgér János , Zsille Ottó , Csurgai József , Feil Ferenc , Vass Gyula , Kátai Urbán Lajos , Dobor József 
Published: August 2021

Computer Program ILT15 was earlier developed to accompany a new leach test for solidified radioactive waste forms in the Hungarian NPP Paks. The program was designed to be used as a tool for performing the calculations necessary to analyze leach test data, a modelling program to determine if diffusion is the operating leaching mechanism (and, if not, to indicate other possible mechanisms), and a means to make extrapolations using the diffusion models. The program uses computational algorithm of ASTM C1308 standard. Now we have developed another computational algorithm based on a Partial Differential Equation (PDE) of a cylindrical specimen, solved the PDE by a Crank-Nicolson Finite Difference Method (FDM) and calculated by integration the eluted amount of a given component in time. The new solution more accurate method was integrated into the existing ILT15 computer program and the resulting new ILT20 program is able to calculate the Incremental/Cumulative Fraction Leached IFL/CFL) either by ASTM or PDE numerical solution methods.ILT20 program is written in C++ in the Borland C++ Builder programming environment. A detailed description of application of this upgraded modelling computer program is given.
Compound Flooding: Dependence at Sub-daily Scales Between Extreme Storm Surge and Fluvial Flow
Authors: Robins Peter E. , Lewis Matt J. , Elnahrawi Mariam , Lyddon Charlotte , Dickson Neil , Coulthard Tom J. 
Published: August 2021

Estuaries are potentially exposed to compound flooding where weather-driven extreme sea levels can occur synchronously with extreme fluvial discharge to amplify the hazard. The likelihood of compound flooding is difficult to determine due to multiple interacting physical processes operating at sub-daily scales, and poor observation records within estuaries with which to determine potential future probabilistic scenarios. We hypothesize that fluvial extremes can occur within the peak of the surge in small/steep catchments because of rapid runoff times, whilst the length-scale in larger/flatter catchments will result in fluvial and marine extremes being out-of-phase. Data (15 min river flow and hourly sea level) spanning 40 years were analyzed to assesses the behaviour and timings of fluvial and sea level extremes in two contrasting estuaries: Humber and Dyfi (United Kingdom). Compound events were common in the Dyfi, a small/steep catchment on Britain’s west coast with fast fluvial response times. Almost half of the 937 skew-surge events (95th-percentile) occurred within a few hours of an extreme fluvial peak, suggesting that flood risk is sensitive to the storm timing relative to high tide—especially since flows persisted above the 95th-percentile typically for less than 12 h. Compound events were more frequent during autumn/winter than spring/summer. For the Humber, a larger/flatter catchment on the east coast with slower fluvial response times, extreme fluvial and skew-surge peaks were less frequent (half as many as the Dyfi) and compound events were less common (15% of events co-occurred). Although flows in the Humber persisted above the 95th-percentile for typically between one and 4 days, hence overlapping several high tides and possibly other surges. Analysis of 56 flooding events across both estuaries revealed: 1) flooding is more common in the Dyfi than Humber; 2) Dyfi flooding is driven by 99th-percentile flows lasting hours and co-occurring with a 95th percentile skew-surge; 3) Humber flooding was driven by 95th-percentile flows lasting days, or surge-driven—but rarely co-occurring. Our results suggest that compound flooding studies require at least hourly data (previous analyses have often used daily-means), especially for smaller systems and considering the potential intensification of rainfall patterns into the future.
Revealing 60 years of Earthquake Swarms in the Southern Red Sea, Afar and the Gulf of Aden
Authors: Ruch Joël , Keir Derek , Passarelli Luigi , Di Giacomo Domenico , Ogubazghi Ghebrebrhan , Jónsson Sigurjón 
Published: August 2021

Earthquake swarms occur sporadically at divergent plate boundaries but their recurrence over multiple decades and relation to magmatic spreading activity remain poorly understood. Here we study more than 100 earthquake swarms over a 60-year period in the southern Red Sea, Afar, and Gulf of Aden region. We first compiled an earthquake-swarm catalogue by integrating reexamined global and local earthquake catalogues from 1960 to 2017. This yielded 134 earthquake swarms that mainly cluster in 19 different areas in the study region, showing that in most cases swarms recur every few decades in the same area. The swarms exhibit a range of earthquake magnitudes and often include multiple M3 to M5 events with some swarms having occasional larger earthquakes over M6, primarily in southern Afar. Many of the earthquake swarms were clearly associated with rifting events, consisting of magmatic intrusions, surface faulting, and in some cases volcanic eruptions. Together, the swarms suggest that extension at these divergent plate boundaries occurs episodically along &lt;100 km long segments, some of which were previously unrecognized. Within the study region, the Gulf of Aden shows the most frequent swarm activity, followed by Afar and then the southern Red Sea. The results show that the three areas were subject to an increase of earthquake-swarm activity from 2003 to 2013 in the form of three rifting episodes and at least seven volcanic eruptions. We interpret that the most likely controls on temporal variations in earthquake swarm activity are either temporal variations in magma supply, or rifting-induced stress change that trigger clusters of swarms.
Oocyte Degeneration After ICSI Is Not an Indicator of Live Birth in Young Women
Authors: Hu Xiaokun , Liu Yuliang , Zhang Xiubing , Lee Pingyin , Wen Yangxing , Ding Chenhui , Zhou Canquan , Xu Yanwen 
Published: August 2021

IntroductionIntracytoplasmic sperm injection (ICSI) was introduced in 1990s as one of the most dramatic breakthroughs in assisted reproductive technology. Even with advances in ICSI technology, this mechanical micromanipulation carries a 5 to 19% risk of oocyte degeneration. Whether the presence of oocyte degeneration reflects the sibling oocyte quality and predicts the sibling embryo development potential and clinical pregnancy outcomes remains controversial. There is no study showing the competence of the sibling embryos from the prospective of cumulative live birth rate. Whether oocyte degeneration is associated with poor quality of the remainder of the cohort remains further to be elucidated.MethodThis retrospective observational study included a total of 488 OPU cycles underwent ICSI with fresh cleavage stage embryo transfer and successive frozen/thawed embryo transfer (FET) cycles from January 2018 to December 2019. All female patients were under the age of 35 years, and underwent ICSI with or without oocyte degeneration (OD). Cycles with at least one oocyte degenerated were defined as oocyte degeneration group (OD group), and cycles with no oocyte degenerated were defined as non-OD group. The OD group was further divided to three subgroups according to different oocyte degeneration rate (&lt;10%, 10-20%, and &gt;20%).ResultsThere were no significant differences with regards to implantation rate (38.5% vs 35.1%, P=0.302), clinical pregnancy rate (54.9% vs 50.3%, P=0.340), and LBR per OPU cycle (47.0% vs 42.9%, P=0.395) between OD and non-OD groups. Initial gonadotropin dosage, E2 level on hCG day and the number of matured oocytes appeared to be independent risk factors for OD. The adjusted odds ratio of live birth rate per OPU cycle were similar in different oocyte degeneration rate subgroups. The ongoing pregnancy/LBR per transfer in FET cycles was not significantly different between OD group and non-OD groups (38.8% vs 43.9%, P=0.439). The cumulative LBR per OPU cycle was also comparable between OD and non-OD group (63.4% vs 64.8%, P=0.760).ConclusionThe results provide cycle-based evidence that the presence of oocyte degeneration after ICSI is not an indicator for predicting the cumulative live birth rate per OPU cycle in young women.
Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis
Authors: Zheng Hanrui , Liu Min , Li Sheyu , Shi Qingyang , Zhang Shengzhao , Zhou Yiling , Su Na 
Published: August 2021

BackgroundSodium-glucose-cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control and lowering body weight in patients with type 2 diabetes mellitus. However, the efficacy and safety on weight loss in adults with overweight or obesity but not diabetes remain unclear. In this article, we aimed to identify the efficacy and safety of SGLT2 inhibitors in adults with overweight or obesity but not diabetes in randomized controlled studies (RCTs).MethodsWe searched for RCTs concerning SGLT2 inhibitors in adults with overweight or obesity but not diabetes in Medline (Ovid SP), Embase (Ovid SP), Cochrane Central Register of Controlled Trials (Ovid SP), and ClinicalTrials.gov up to February 2021. The primary outcomes were changes in body weight and body mass index (BMI). Trial sequential analysis (TSA) was used to test the reliability of the primary outcomes. We analyzed the data using Review Manager 5.3 and pooled data to calculate the mean differences (MDs) or the relative risk (RR). We assessed the evidence quality of evidence of outcomes according to GRADE.ResultsSix randomized controlled trials involving 872 individuals were included in the meta-analysis. Compared to the placebo group, the SGLT2 inhibitors group had statistically significant reductions in absolute changes in body weight (MD: -1.42 kg, 95% CI: -1.70 to -1.14; P&lt;0.00001) and BMI (MD: -0.47 kg/m2, 95% CI: -0.63 to -0.31; P&lt;0.00001) in SGLT2 inhibitors group, as indicated by TSA. However, no significant benefits were observed in the SGLT2 inhibitors group in terms of waist circumference (MD: -1.34 cm, 95%CI: -2.75 to 0.07; Z=1.86, P=0.06) compared with the placebo group. The GRADE profiles indicated very low-quality evidence for body weight change and low-quality evidence for BMI change. SGLT2 inhibitors were generally safe and well tolerated.ConclusionSGLT2 inhibitors could be used in selected adults with overweight and obesity but not diabetes if they are at low risk of genital infection and urinary infection. Further studies are warranted to confirm the efficacy and safety of SGLT2 inhibitors in adults with overweight or obesity but not diabetes for long-term weight management.Systematic Review Registration[https://www.crd.york.ac.uk/prospero/#loginpage], identifier [PROSPERO, CRD42021252931]
The “GEnomics of Musculo Skeletal Traits TranslatiOnal NEtwork”: Origins, Rationale, Organization, and Prospects
Authors: Koromani Fjorda , Alonso Nerea , Alves Ines , Brandi Maria Luisa , Foessl Ines , Formosa Melissa M. , Morgenstern Milana Frenkel , Karasik David , Kolev Mikhail , Makitie Outi , Ntzani Evangelia , Pietsch Barbara Obermayer , Ohlsson Claes , Rauner Martina , Soe Kent , Soldatovic Ivan , Teti Anna , Valjevac Amina , Rivadeneira Fernando 
Published: August 2021

Musculoskeletal research has been enriched in the past ten years with a great wealth of new discoveries arising from genome wide association studies (GWAS). In addition to the novel factors identified by GWAS, the advent of whole-genome and whole-exome sequencing efforts in family based studies has also identified new genes and pathways. However, the function and the mechanisms by which such genes influence clinical traits remain largely unknown. There is imperative need to bring multidisciplinary expertise together that will allow translating these genomic discoveries into useful clinical applications with the potential of improving patient care. Therefore “GEnomics of MusculoSkeletal traits TranslatiOnal NEtwork” (GEMSTONE) aims to set the ground for the: 1) functional characterization of discovered genes and pathways; 2) understanding of the correspondence between molecular and clinical assessments; and 3) implementation of novel methodological approaches. This research network is funded byThe European Cooperation in Science and Technology(COST). GEMSTONE includes six working groups (WG), each with specific objectives: WG1-Study populations and expertise groups:creating, maintaining and updating an inventory of experts and resources (studies and datasets) participating in the network, helping to assemble focus groups defined by phenotype, functional and methodological expertise. WG2-Phenotyping:describe ways to decompose the phenotypes of the different functional studies into meaningful components that will aid the interpretation of identified biological pathways. WG3Monogenic conditions - human KO models:makes an inventory of genes underlying musculoskeletal monogenic conditions that aids the assignment of genes to GWAS signals and prioritizing GWAS genes as candidates responsible for monogenic presentations, through biological plausibility. WG4Functional investigations: creating a roadmap of genes and pathways to be prioritized for functional assessment in cell and organism models of the musculoskeletal system. WG5Bioinformaticsseeks the integration of the knowledge derived from the distinct efforts, with particular emphasis on systems biology and artificial intelligence applications. Finally, WG6Translational outreach: makes a synopsis of the knowledge derived from the distinct efforts, allowing to prioritize factors within biological pathways, use refined disease trait definitions and/or improve study design of future investigations in a potential therapeutic context (e.g. clinical trials) for musculoskeletal diseases.
Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis
Authors: Xu Qingyu , He Shujiao , Yu Li 
Published: August 2021

BackgroundPrevious trials demonstrated evidence involving the total effects of gemtuzumab ozogamicin (GO), an anti-CD33 humanized antibody, on treating acute myeloid leukemia (AML). In this updated systematic review, meta-analysis, and network meta-analysis (NMA), we aimed to comprehensively explore the clinical benefits and safety of GO in various subtypes of AML.MethodsPubMed, Embase, Cochrane, and Chinese databases were filtered to search randomized controlled trials (RCTs) and retrospective cohort studies that compared clinical efficiency and toxicity of GO with non-GO groups in AML. Random-effects models were used to calculate pooled effect sizes and 95% confidence intervals (CIs). Relative risk (RR) was used for estimating complete remission (CR), early death, and toxicity. Hazard risk (HR) was accomplished to evaluate survival.ResultsFifteen RCTs and 15 retrospective cohort studies were identified (GO: 4,768; Control: 6,466). GO tended to improve CR (RR 0.95, p = 0.084), followed by significantly improved survival (overall survival: HR 0.86, p = 0.003; event-free survival: HR 0.86, p = 0.015; relapse-free survival: HR 0.83, p = 0.001; cumulative incidence of relapse: HR 0.82, p &lt; 0.001). GO benefits of CR and survival were evident in favorable- and intermediate-risk karyotypes (p ≤ 0.023). GO advantages were also associated with nucleophosmin 1 mutations (p ≤ 0.04), wild-type FMS-like tyrosine kinase 3 internal tandem duplication gene (p ≤ 0.03), age of &lt;70 years (p &lt; 0.05), de novo AML (p ≤ 0.017), and CD33(+) (p ≤ 0.021). Both adding GO into induction therapy (p ≤ 0.011) and a lower (&lt;6 mg/m2) dose of GO (p ≤ 0.03) enhanced survival. Prognosis of combined regimens with GO was heterogeneous in both meta-analysis and NMA, with several binding strategies showing improved prognosis. Additionally, GO was related to increased risk of early death at a higher dose (≥6 mg/m2) (RR 2.01, p = 0.005), hepatic-related adverse effects (RR 1.29, p = 0.02), and a tendency of higher risk for hepatic veno-occlusive disease or sinusoidal obstruction syndrome (RR 1.56, p = 0.072).ConclusionsThese data indicated therapeutic benefits and safety of GO in AML, especially in some subtypes, for which further head-to-head RCTs are warranted.Systematic Review Registration[PROSPERO: https://www.crd.york.ac.uk/prospero/], identifier [CRD42020158540].
A Novel Single Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis
Authors: Darden Dijoia B. , Dong Xiaoru , Brusko Maigan A. , Kelly Lauren , Fenner Brittany , Rincon Jaimar C. , Dirain Marvin L. , Ungaro Ricardo , Nacionales Dina C. , Gauthier Marie , Kladde Michael , Brusko Todd M. , Bihorac Azra , Moore Frederick A. , Loftus Tyler , Bacher Rhonda , Moldawer Lyle L. , Mohr Alicia M. , Efron Philip A. 
Published: August 2021

BackgroundWith the successful implementation of the Surviving Sepsis Campaign guidelines, post-sepsis in-hospital mortality to sepsis continues to decrease. Those who acutely survive surgical sepsis will either rapidly recover or develop a chronic critical illness (CCI). CCI is associated with adverse long-term outcomes and 1-year mortality. Although the pathobiology of CCI remains undefined, emerging evidence suggests a post-sepsis state of pathologic myeloid activation, inducing suboptimal lymphopoiesis and erythropoiesis, as well as downstream leukocyte dysfunction. Our goal was to use single-cell RNA sequencing (scRNA-seq) to perform a detailed transcriptomic analysis of lymphoid-derived leukocytes to better understand the pathology of late sepsis.MethodsA mixture of whole blood myeloid-enriched and Ficoll-enriched peripheral blood mononuclear cells from four late septic patients (post-sepsis day 14-21) and five healthy subjects underwent Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq).ResultsWe identified unique transcriptomic patterns for multiple circulating immune cell subtypes, including B- and CD4+, CD8+, activated CD4+ and activated CD8+ T-lymphocytes, as well as natural killer (NK), NKT, and plasmacytoid dendritic cells in late sepsis patients. Analysis demonstrated that the circulating lymphoid cells maintained a transcriptome reflecting immunosuppression and low-grade inflammation. We also identified transcriptomic differences between patients with bacterial versus fungal sepsis, such as greater expression of cytotoxic genes among CD8+ T-lymphocytes in late bacterial sepsis.ConclusionCirculating non-myeloid cells display a unique transcriptomic pattern late after sepsis. Non-myeloid leukocytes in particular reveal a host endotype of inflammation, immunosuppression, and dysfunction, suggesting a role for precision medicine-guided immunomodulatory therapy.
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Authors: Xu Qian , Zhang Xue , Huang Miao , Dai Xin , Gao Jing , Li Song , Sheng Lei , Huang Kai , Wang Jian , Liu Lian 
Published: August 2021

BackgroundImmune checkpoint inhibitors (ICIs) have improved survival for advanced wild-type non-small cell lung cancer (NSCLC) significantly, but few studies compared single ICI (SICI)-based treatments and double ICIs (DICI)-based treatments. We summarized the general efficacy of ICI-related treatments, compared the efficacy and safety of SICI-based [programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors ± chemotherapy (CT)] and DICI-based (PD-1/PD-L1 inhibitors+CTLA-4 inhibitors ± chemotherapy) treatments vs. CT in the first-line treatment.MethodsWe included phase II/III randomized controlled trials (RCTs), including patients with histologically confirmed stage IIIB–IV driver-gene wild-type NSCLC who received first-line ICI-related therapy in at least one arm. PubMed, Embase, and Cochrane Library were searched from January 1, 2005, to December 31, 2020. This network meta-analysis was performed in a Bayesian framework using GEMTC and JAGS package in R.3.6.1. The research was registered with PROSPERO (CRD42020184534).ResultsTwenty RCTs were involved, including 13,032 patients and 17 treatment regimens. The results showed that ICI-based therapies could provide a pooled median overall survival (mOS) (POS) of 15.79 (95% CI: 14.85–16.73) months, and there were no significant differences in OS, progression-free survival (PFS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs) between DICI-based treatments (POS: 14.81, 12.11–17.52 months) and SICI-based treatments (POS: 16.17, 14.59–17.74 months) in overall patients. However, DICI-based treatments had significantly prolonged the OS over SICI-based treatments in squamous and PD-L1 &lt;1% subgroups. The ranking of OS benefit by Bayesian surface under the cumulative ranking curve (SUCRA) spectrum showed that DICI+chemotherapy ranked first for overall population and subgroups including squamous, non-squamous, any level of PD-L1 expression, smoking, male, Eastern Cooperative Oncology Group performance status (ECOG PS) = 0/1, age &lt; 65/≥65 while SICI+CT for low tumor mutation burden (TMB), non-smoking, and female subgroups, and DICI for high TMB subgroups.ConclusionsIn the first-line therapy for advanced wild-type NSCLC, both SICI- and DICI-based treatments could bring significant overall advantages over chemotherapy, with comparable outcomes of efficacy and ≥3AEs. DICI-based treatments were more effective than SICI-based treatments in squamous and PD-L1 &lt;1% subgroups. For most populations, DICI+chemotherapy could be the best choice with a survival benefit, while SICI+chemotherapy has established its position actually.Systematic Review Registration[PROSPERO], identifier [CRD42020184534].